Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV

Emerald Advisers LLC raised its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 30.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,351,254 shares of the specialty pharmaceutical company’s stock after purchasing an additional 313,205 shares during the period. Emerald Advisers LLC owned 2.67% of KalVista Pharmaceuticals worth $16,458,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. BNP Paribas Financial Markets boosted its stake in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares in the last quarter. Wolverine Asset Management LLC bought a new position in KalVista Pharmaceuticals in the third quarter worth approximately $57,000. KLP Kapitalforvaltning AS purchased a new stake in KalVista Pharmaceuticals during the third quarter worth $63,000. Virtus Investment Advisers LLC purchased a new stake in KalVista Pharmaceuticals during the second quarter worth $81,000. Finally, Tower Research Capital LLC TRC boosted its position in KalVista Pharmaceuticals by 816.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock valued at $91,000 after acquiring an additional 7,180 shares in the last quarter.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 5,296 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider owned 131,831 shares in the company, valued at $1,773,126.95. This trade represents a 3.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Brian Piekos sold 4,471 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the sale, the chief financial officer directly owned 10,529 shares of the company’s stock, valued at approximately $141,615.05. This represents a 29.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 31,329 shares of company stock valued at $437,371 in the last ninety days. Company insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Stock Up 3.9%

KALV stock opened at $15.91 on Thursday. The firm has a 50 day moving average of $15.21 and a 200 day moving average of $13.80. The stock has a market capitalization of $804.25 million, a PE ratio of -4.03 and a beta of -0.14. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 52 week low of $8.40 and a 52 week high of $19.00.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million for the quarter, compared to analyst estimates of $6.03 million. Sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on KALV. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Citizens Jmp decreased their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th. HC Wainwright raised their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Finally, Needham & Company LLC lifted their price objective on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.